Menu
Recruiting NCT05443841

Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)

— Observational Esophageal Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: pleural lavage.
Who it may be relevant to
Registry conditions: Esophageal Cancer. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Prospective Study for Pleural Lavage Cytology in Patients With Esophageal Cancer

Overview

Disease recurrence and metastasis are common after curative treatment for patients with esophageal cancer. Thus, it is important to identify the risk factors to predict disease recurrence and metastasis. Pleural lavage cytology (PLC) is reported to be associated with disease recurrence and patient survival in lung cancer, but the value is unclear in esophageal cancer. The aim of this study is to evaluate the value of PLC in esophageal cancer patient in terms of frequencies, association with patient survival, and efficacy of postoperative treatment.

Detailed description

Pleural lavage cytology will be performed before esophageal resection, and after resection, respectively. Frequency of positive pleural lavage cytology will be determined, and the value of pleural lavage cytology for patients with resectable esophageal cancer will be studied.

Interventions

  • Other pleural lavage
    pleural lavages before tumor resection and after tumor resecion, respectively

Primary outcome measures

  • number of patients who had positive pleural lavage cytology [Time frame: July 2022 to July 2023]
Secondary outcome measures (1)
  • Time period from date of surgery to the date of death [Time frame: July 2022 to July 2026]

Eligibility criteria

Inclusion criteria

  • esophageal cancer with histological confirmation before treatment.
  • resectable esophageal cancer with clinical T1-4a/N0-3/M0 staging
  • potential R0 resection
  • no history of other malignancies

Exclusion criteria

  • severe major organ dysfunction (American society of anesthesiologisits score >3 )
  • patients underwent ESD or EMR
  • pleural lavage is unavailable due to adhesions

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 11 centers
  • The First Affiliated Hospital of USTC — Hefei
  • The Fourth Hospital of Hebei Medical University — Shijiazhuang
  • Henan Provincial People's Hospital — Zhengzhou
  • Nantong Tumor Hospital — Nantong
  • The Second Affiliated Hospital of Nantong University — Nantong
  • Taixing People's Hospital — Taishing
  • Taizhou People's Hospital — Taizhou
  • Shaanxi Provincial cancer Hospital — Xi'an
  • … and 3 more centers

Identifiers

NCT: NCT05443841 · ECTOP-2005

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗